3-羟基克拉霉素和2＇-乙酰基-3-氧代克拉霉素的合成与晶体结构

克拉霉素在不同条件下水解,分别生成3-羟基克拉霉素（2）和3-羟基-8,9,10,11-二脱水-9,12-半缩酮克拉霉素（3）,用乙酸酐保护2的C（2’）-OH得到2’-乙酰基-3-羟基克拉霉素（4）,用N-氯代琥珀酰亚胺（NCS）氧化4的C（3）-OH合成了2’-乙酰基-3-氧代克拉霉素（5）,采用MS,IR,^1H NMR,^13C NMR等对这些化合物进行了表征．用X射线单晶衍射法测定了化合物2和5的晶体结构,其均属于正交晶系,P212121空间群．化合物2的晶胞参数a=1．3657（3）nm,b=1．4783（3）nm,c=1．6510（3）nm,Z=4,V=3．3332（12）nm^3,Dc=1．175g／cm^3,F（000）=1288,／t=0．087mm^-1;化合物5的晶胞参数a=1．5124（3）nm,b=1．5247（3）nm,c=1．5288（3）nm,Z=4,V=3．5254（12）nm^3,Dc=1．187g／cm^3,F（000）=1368．0,μ=0．088mm^-1．     

3-羟基克拉霉素和2′-乙酰基-3-氧代克拉霉素的合成与晶体结构

克拉霉素在不同条件下水解, 分别生成3-羟基克拉霉素(2)和3-羟基-8,9,10,11-二脱水-9,12-半缩酮克拉霉素(3), 用乙酸酐保护2的C(2’)-OH得到2′-乙酰基-3-羟基克拉霉素(4), 用N-氯代琥珀酰亚胺(NCS)氧化4的C(3)—OH合成了2’-乙酰基-3-氧代克拉霉素(5), 采用MS, IR, 1H NMR, 13C NMR等对这些化合物进行了表征. 用X射线单晶衍射法测定了化合物2和5的晶体结构, 其均属于正交晶系, P212121 空间群. 化合物2的晶胞参数a＝1.3657(3) nm, b＝1.4783(3) nm, c＝1.6510(3) nm, Z＝4, V＝3.3332(12) nm3, Dc＝1.175 g/cm3, F(000)＝1288, μ＝0.087 mm－1; 化合物5的晶胞参数 a＝1.5124(3) nm, b＝1.5247(3) nm, c＝1.5288(3) nm, Z＝4, V＝3.5254(12) nm3, Dc＝1.187 g/cm3, F(000)＝1368.0, μ＝0.088 mm－1.     

2-乙氨基-6H-5-(1-苯基-3-甲基/苯基-5-吡唑啉酮-4-基)-1,3,4-噻二嗪的合成和晶体结构

利用1-苯基-3-甲基/苯基-4-氯乙酰基-吡唑啉酮-5(PMCP/DPCP)与4-乙基氨基硫脲(ETSC)发生缩合反应,生成了2个新的双杂环化合物2-乙氨基-6H-5-(1-苯基-3-甲基/苯基-5-吡唑啉酮-4-基)-1,3,4-噻二嗪(PMCP-ETSC/DPCP-ETSC),并对其进行元素分析、红外光谱、核磁共振表征和晶体结构分析.PMCP-ETSC晶体属于单斜晶系,Pm空间群,晶胞参数:a=0.7947(1)nm,b=0.8348(1)nm,c=1.1990(2)nm,β=106.07(1)°,V=0.77269(2)nm3,Z=2,Dc=1.356g/cm3,μ=0.219mm-1,F(000)=332,R=0.0298,wR=0.0704.该化合物通过分子间氢键形成沿c轴无限延伸的一维链状结构.DPCP-ETSC晶体属于正交晶系,Pna21空间群,晶胞参数:a=1.1478(2)nm,b=1.3545(2)nm,c=1.1994(2)nm,V=1.8646(4)nm3,Z=4,Dc=1.345g/cm3,μ=0.194mm-1,F(000)=792,R=0.0345,wR=0.0694,此化合物通过分子间氢键形成沿c轴成链状,沿ab平面成波浪状的超分子结构.     

水合5-(4-羟基苯酚)四氮唑的溶剂热合成及其晶体结构

以4-羟基苯氰为原料,用溶剂热法合成了水合5-(4-羟基苯酚)四氮唑晶体[(C7H6N4O)·1.5H2O,1],其结构经1H NMR,IR,元素分析及X-单晶衍射表征.1属单斜晶系,C2/c空间群,晶胞参数:a=1.487 2(3) nm,b=0.992 3(2) nm,c=1.304 8(2) nm,β=113.724(3)°,V=1.762 8(5) nm3,Dc=1.365 g*cm-3,F(000)=760,Z=8,μ(MoKα)=0.104 mm-1,R1=0.050 5,wR2=0.117 6.1中存在强烈的分子间氢键和π-π堆积作用.     

2-(4'-羧基苯基)-1,2-苯并异硒唑-3(H)-酮的合成与晶体结构及抑菌活性

以邻氨基苯甲酸为原料,通过重氮化、二硒醚化、氯化和缩合反应,合成得到2-(4'-羧基苯基)-1,2-苯并异硒唑-3(H)-酮,化合物结构经HR-MS、~1H NMR、~(13)C NMR表征,采用XRD测定其单晶结构,该晶体属于单斜晶系,P21/c空间群,晶胞参数a=2.0641(3)nm,b=0.5000(17)nm,c=1.2046(1)nm,β=97.495(3)°,V=1.2326(6)nm~3,Dc=1.715 g·cm~3,Z=4,F(000)=632.0。初步抑菌试验发现该化合物对金黄色葡萄球菌和大肠杆菌有一定的抑菌活性(CCDC:1576226)。     

3-二茂铁基二氢吡唑衍生物的合成及晶体结构

以乙酰基二茂铁为原料合成了6种二茂铁取代的4,5-二氢吡唑化合物,用IR、MS、1H NMR测试技术对其结构进行了表征,并采用X射线衍射方法测定了化合物2b的晶体和分子结构。C30H26Fe2N2O(化合物2b)属于三斜晶系,空间群P1,晶胞参数：a=0.9275(4) nm,b=1.1327(5) nm,c=1.1912(5) nm,α=88.67(2)°,β=79.925(18)°,γ=70.345(18)°,V=1.1595(9) nm3,Z=2,F(000)=560,Dc=1.553 g/cm3,μ=1.279 mm-1,R1=0.0351,wR2=0.0934。     

3-叠氮-4-氨基呋咱的合成及其晶体结构

以乙二醛和盐酸羟胺为原料,经加成,闭环和氮化反应制备了新型含能化合物3-叠氮-4-氨基呋咱(AAF),其结构经NMR,IR,X-射线单晶衍射仪及元素分析表征。AAF晶体属单斜晶系,P21/c空间群,晶胞参数为:a=0.5329(16)nm,b=1.0722(3)nm,c=0.8492(2)nm,α=90.00°,β=99.03(2)°,γ=90.00°,V=0.5046(2)nm3,Dc=1.660g.cm-3,Z=4,F(000)=256,μ(MoKα)=0.138mm-1。最终偏离因子R1=0.0768,wR2=0.1983。AAF晶体存在分子间氢键。     

4-苯氨基喹唑啉类衍生物的合成、表征及晶体结构

以香草醛为原料,经过7个步骤合成得到了12个新的4-苯氨基喹唑啉类化合物8a～81,产物的结构经1H NMR,13C NMR,IR,MS和元素分析确认,并用X射线衍射法测定化合物8b的晶体结构.化合物8b属三斜晶系,P-l空间群,晶胞参数:α=0.8868(5)nm,b=1.0239(6)nm,c=1.4515(9)nm,α=71.02(2)°,β=82.42(2)°,γ=71.78(2)°,V=1.1831 um3,Z=2,Dc=1.430Mg/m3,μ(MoKα)=1.773mm-1,λ=0.071073nm,F(000)=522.     

3-[(1H-1,2,4-三唑-1-基)甲基]-1,1′-联萘酚的合成及晶体结构

成功地合成了化合物rac-3-[(1H-1,2,4-三唑-1-基)甲基]-1,1′-联萘酚,利用X射线单晶衍射确定了其空间结构;与此同时,利用1H NMR1、3C NMR和元素分析确认了所合成的中间体及目标产物的化学结构.结果表明,目标化合物晶体属于单斜晶系,P21/C空间群,晶胞参数a=1.141 39(10)nm,b=0.955 53(8)nm,c=1.688 16(14)nm,β=97.305(4)°,V=1.826 2(3)nm3,Z=4,Dc=1.336 g/cm3,F(000)=768,wR=0.105 9.目标分子通过分子间氢键作用相互堆积,形成空间三维结构.     

3-{2-([5,6]-咪唑-1,10-邻菲咯啉)]}-3′-甲酸-2,2’-联吡啶的合成和晶体结构

以1,10-邻菲咯啉为原料,经三步反应生成了标题化合物,化合物经1H NMR,MS和X-射线单晶衍射表征.结果表明,化合物晶体为单斜晶系,空间群,P21/c,a=1.24828(16)nm,b=1.18534(15)nm,c=1.37542(16)nm,α=90.00°,β=109.268(4)°,γ=90.00°,V=1.9211(4)nm3,Z=4,Mr=418.41,Dc=1.440g.cm-3,μ=0.097mm-1,F(000)=856,R1=0.0633,wR2=0.1803.CCDC:728109.     

Synthesis and Dehydrobromination of 3-Bromomethyl- and 3-Bromo-3-methoxymethylcyclobutane-1-carbonitriles and Methyl 3-Bromomethyl- and 3-Bromo-3-methoxymethylcyclobutane-1-carboxylates

The anti-Markownikoff products of bromination and bromomethoxylation of 3-methylenecyclobutane-1-carbonitrile and methyl 3-methylenecyclobutane-1-carboxylate were subjected to dehydrobromination by the action of potassium tert-butoxide in THF. The reaction takes two elimination pathways: 1,3-dehydrobromination to give bicyclobutane derivatives and 1,2-dehydrobromination leading to substituted methylenecyclobutane. Structural factors in the substrate were revealed, which are responsible for the ratio of the two concurrent elimination processes.     

3-cyclobutyl-3-ferrocenylcyclopropene and 3-cyclobutylidene-3-ferrocenylpropyne Synthesis and chemical properties

3-Cyclobutyl-3-ferrocenylcyclopropene was synthesized by the reactions of mono- or dibromoferrocenylcyclopropanes with Bu^tOK in DMSO. Treatment of dibromoferro-cenylcyclopropane with Bu^tOK in THF afforded 3-cyclobutylidene-3-ferrocenylpropyne in 52% yield. Heterolysis of the C-C bond in the three-membered ring of 3-cyclobutyl-3-ferrocenylcyclopropene at low and high temperatures was studied. Hydrolysis yielded 3-cyclobutyl-1H-cyclopentaferrocene and products with linear structures,viz., 3-cyclobutylidene-3-ferrocenylpropene,E- andZ-I-ferrocenyl-1-cyclobutylpropenes, and 1-cyclobutylidene-1-ferrocenylacetone. Cyclopropene reacts with 1,3-diphenylisobenzofuran to form two Diels-Alder adducts, while the enyne does not react with 1,3-diphenylbenzofuran. Facultad de Quimica, Universidad Nacional Autónoma de México, Cd. Universitaria, C.P. 04510, México D. F., México. Translated fromIzvestiya Akademii Nauk. Seriya Khimicheskaya, No. 11, pp. 2177–2181, November, 1999.     

3-Epistrophanthidin and 3-epistrophanthidol

Conclusions The hydrolysis of the total glycosides of the seeds ofStrophanthus kombé Oliv. and the adsorption-chromatographic separation of the mixture of aglycones has given strophanthidin, strophanthidol, 17-H-strophanthidin, and two new cardenolides denoted by the symbols IM-38 and IM-40 in the individual state. On the basis of the investigations carried out, the new cardenolides have been characterized provisionally as 3-epistrophanthidin and 3-epistrophanthidol.Khimiya Prirodnykh Soedinenii, Vol. 5, No. 6, pp. 508–511, 1969     

3-Trifluoromethyl- and 3-difluoromethyl-thalidomides

Syntheses of racemic 3-trifluoromethyl- and 3-difluoromethyl-thalidomide starting from 2-(tert-butyloxycarbonylimino)-3,3,3-trifluoropropionate or -3,3-difluoropropionate as fluorine-containing building blocks are described.     

Syntheses and Crystal Structures of BaAgTbS3, BaCuGdTe3, BaCuTbTe3, BaAgTbTe3, and CsAgUTe3

Five new quaternary chalcogenides of the 1113 family, namely BaAgTbS₃, BaCuGdTe₃, BaCuTbTe₃, BaAgTbTe₃, and CsAgUTe₃, were synthesized by the reactions of the elements at 1173–1273 K. For CsAgUTe₃ CsCl flux was used. Their crystal structures were determined by single‐crystal X‐ray diffraction studies. The sulfide BaAgTbS₃ crystallizes in the BaAgErS₃ structure type in the monoclinic space group C³,_2h‐C2/m, whereas the tellurides BaCuGdTe₃, BaCuTbTe₃, BaAgTbTe₃, and CsAgUTe₃ crystallize in the KCuZrS₃ structure type in the orthorhombic space group D¹_,2⁷_,h‐Cmcm. The BaAgTbS₃ structure consists of edge‐sharing [TbS₆^9–] octahedra and [AgS₅^9–] trigonal pyramids. The connectivity of these polyhedra creates channels that are occupied by Ba atoms. The telluride structure features ²_∞[MLnTe₃^2–] layers for BaCuGdTe₃, BaCuTbTe₃, BaAgTbTe₃, and ²_∞[AgUTe₃^1–] layers for CsAgUTe₃. These layers comprise [MTe₄] tetrahedra and [LnTe₆] or [UTe₆] octahedra. Ba or Cs atoms separate these layers. As there are no short Q ··· Q (Q = S or Te) interactions these compounds achieve charge balance as Ba²⁺M⁺Ln³⁺(Q^2–)₃ (Q = S and Te) and Cs⁺Ag⁺U⁴⁺(Te^2–)₃.